Indian Glenmark Pharmaceuticals has been granted final approval by the U.S. FDA for Ezetimibe and Simvastatin Tablets, for several doses.
Glenmark said that, referring to to IQVIA sales data for the 12-month period ending April 2019, the Vytorin Tablets market achieved annual sales of approximately $92.4 million.
Glenmark’s current portfolio consists of 157 products authorized for distribution in the U.S. marketplace and 58 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.